share_log

CFO & Treasurer Of Merit Medical Systems Sold 46% Of Their Shares

CFO & Treasurer Of Merit Medical Systems Sold 46% Of Their Shares

Merit Medical Systems的首席財務官兼財務主管出售了46%的股份
Simply Wall St ·  03/15 06:35

Anyone interested in Merit Medical Systems, Inc. (NASDAQ:MMSI) should probably be aware that the CFO & Treasurer, Raul Parra, recently divested US$479k worth of shares in the company, at an average price of US$73.95 each. That sale was 46% of their holding, so it does make us raise an eyebrow.

任何對Merit Medical Systems, Inc.(納斯達克股票代碼:MMSI)感興趣的人都應該知道,首席財務官兼財務主管勞爾·帕拉最近剝離了該公司價值47.9萬美元的股份,平均每股價格爲73.95美元。那次出售佔他們持股量的46%,因此確實讓我們大吃一驚。

Merit Medical Systems Insider Transactions Over The Last Year

Merit Medical Systems 去年內幕交易

Notably, that recent sale by Raul Parra is the biggest insider sale of Merit Medical Systems shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$71.93. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

值得注意的是,勞爾·帕拉最近的出售是我們去年對Merit Medical Systems股票的最大一次內幕出售。因此,我們知道一位內部人士以目前的71.93美元左右的股價出售了股票。我們通常不喜歡看到內幕銷售,但是銷售價格越低,我們就越擔心。鑑於此次出售是以當前價格進行的,這使我們有點謹慎,但並不是一個主要問題。

Insiders in Merit Medical Systems didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

去年,Merit Medical Systems的內部人士沒有購買任何股票。下圖顯示了去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NasdaqGS:MMSI Insider Trading Volume March 15th 2024
納斯達克GS: MMSI 內幕交易量 2024 年 3 月 15 日

I will like Merit Medical Systems better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡Merit Medical Systems的。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。

Does Merit Medical Systems Boast High Insider Ownership?

Merit Medical Systems 是否擁有很高的內部所有權?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 2.3% of Merit Medical Systems shares, worth about US$99m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我們通常希望看到相當高的內部所有權水平。內部人士擁有Merit Medical Systems2.3%的股份,價值約9900萬美元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。

So What Does This Data Suggest About Merit Medical Systems Insiders?

那麼,這些數據對Merit Medical Systems內部人士有什麼啓示呢?

Insiders haven't bought Merit Medical Systems stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. On the plus side, Merit Medical Systems makes money, and is growing profits. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 1 warning sign for Merit Medical Systems you should know about.

內部人士在過去三個月中沒有購買Merit Medical Systems的股票,但出現了一些拋售。展望過去的十二個月,我們的數據並未顯示任何內幕買盤。從好的方面來看,Merit Medical Systems賺了錢,而且利潤也在增長。儘管內部人士確實擁有股票,但他們並不擁有大量股票,他們一直在拋售。購買前我們會謹慎行事!因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。每家公司都有風險,我們發現了一個你應該知道的Merit Medical Systems警告信號。

But note: Merit Medical Systems may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:Merit Medical Systems可能不是最好的買入股票。因此,來看看這份投資回報率高、債務低的有趣公司的免費清單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論